Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.
Juan Badimon, PhD
Advertisement
Juan Badimon, PhD, is a professor of medicine and the director of the Atherothrombosis Research Unit at the Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai.
Articles by Juan Badimon, PhD
Advertisement
